Abstract
Imaging phenotypes extracted via radiomics of magnetic resonance imaging have shown great potential in predicting the treatment response in breast cancer patients after administering neoadjuvant systemic therapy (NST). Understanding the causal relationships between the treatment response and Imaging phenotypes, Clinical information, and Molecular (ICM) features are critical in guiding treatment strategies and management plans. Counterfactual explanations provide an interpretable approach to generating causal inference. However, existing approaches are either computationally prohibitive for high dimensional problems, generate unrealistic counterfactuals, or confound the effects of causal features by changing multiple features simultaneously. This paper proposes a new method called Sparse CounteRGAN (SCGAN) for generating counterfactual instances to reveal causal relationships between ICM features and the treatment response after NST. The generative approach learns the distribution of the original instances and, therefore, ensures that the new instances are realistic. We propose dropout training of the discriminator to promote sparsity and introduce a diversity term in the loss function to maximize the distances among generated counterfactuals. We evaluate the proposed method on two publicly available datasets, followed by the breast cancer dataset, and compare their performance with existing methods in the literature. Results show that SCGAN generates sparse and diverse counterfactual instances that also achieve plausibility and feasibility, making it a valuable tool for understanding the causal relationships between ICM features and treatment response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors are grateful for the kind support provided by NIBIB of the National Institutes of Health under award number R21EB033923-01, ASU-Mayo Clinic Seed Grant, the Gerstner Family and the Brandt Young Scholarship from the Centers of Individualized Medicine and ASU-Mayo Clinic Summer residency program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=70226903
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We have 1. Revised the literature review section to clearly highlight the gaps and the novelty of our proposed work. 2. Provided description on the properties of counterfactuals and how our approach achieves them. We have also corrected the typographical errors and other notational issues raised by the reviewers. 3. Conducted an additional simulation study to validate the feasibility of counterfactuals.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
